Prostrakan Group

Orexo: UK Marketing Approval Issued For Abstral For The Treatment Of Cancer Pain

Medical News Today (Free subscription) | 23/09/2008

Orexo AB (STO:ORX) confirms the announcement made by ProStrakan Group plc (LSE:PSK), Orexo's partner for Abstral® in Europe and North America, that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Marketing Authorisation for Abstral (for breakthrough cancer pain). As a result of the approval, Orexo will receive a milestone payment of USD 1 million.

The First And Only Patch For Preventing Nausea And Vomiting In Cancer Patients Undergoing Chemotherapy

Medical News Today (Free subscription) | 16/09/2008

ProStrakan Group plc (LSE: PSK) has announced the U.S. Food and Drug Administration (F.D.A) approval of SANCUSO® (Granisetron Transdermal System), the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately and/or highly nausea-inducing chemotherapy regimen.

FDA Approves Sancuso Patch

Contract Pharma Breaking News (Free subscription) | 15/09/2008

ProStrakan Group received approval from the FDA for Sancuso (Granisetron Transdermal System), the first patch to provide five days of control of nausea and vomiting for patients undergoing chemotherapy. Chemotherapy-induced nausea and vomiting (CINV) is common among patients undergoing chemotherapy and can lead to dehydration, malnutrition, treatment delay, or even discontinuation of treatment. Sancuso...

• F.D.A. Approves SANCUSO, the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy - Newswise
• F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy - PR News Wire
• See the 4 articles on the same subject

Abstral (Rapinyl) Receives Positive CHMP Opinion For Breakthrough Cancer Pain - Europe

Medical News Today (Free subscription) | 29/06/2008

ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Abstral (formerly branded as Rapinyl), the fast-acting tablet for breakthrough cancer pain.

ProStrakan and JapanBridge Partner to Develop Sancuso(R) in Japan, China & Parts of South East Asia

Red Orbit (Free subscription) | 23/05/2008

ProStrakan Group plc (LSE:PSK) and JapanBridge K.K. announce today an exclusive licence granted to JapanBridge to develop and commercialise Sancuso(R) (granisetron transdermal delivery system) in Japan, China and several other nations throughout South East Asia.

• ProStrakan and JapanBridge Partner to Develop Sancuso(R) in Japan, China & Parts of South East Asia - The Earth Times Online Newspaper
• ProStrakan and JapanBridge Partner to Develop Sancuso(R) in Japan, China & Parts of South East Asia - Business Wire

Orexo: Rapinyl has received Swedish Marketing Authorization

EuroInvestor.co.uk (Free subscription) | 07/03/2008

Rapinyl has received Swedish Marketing Authorization Uppsala, Sweden, 7th March 2008 - Orexo's licensing partner for Rapinylin Europe, ProStrakan Group plc announces that Rapinyl.. - Read more